Cosmochemistry techniques shed light on potential new Alzheimer’s disease biomarker

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

The FDA is rais­ing re­peat safe­ty and ef­fi­ca­cy ques­tions ahead of an ad­vi­so­ry com­mit­tee meet­ing on Thurs­day for Lex­i­con Phar­ma­ceu­ti­cals’ SGLT2 in­hibitor so­tagliflozin, which the

In a Phase III trial, Sanofi’s Sarclisa regimen offered statistically significant PFS improvement in NDMM patients. Credit: Sergiy Palamarchuk/ Shutterstock.com. The US Food and Drug